Roivant Sciences Ltd. (NASDAQ:ROIV) Director Financial Lp Qvt Sells 876,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Financial Lp Qvt sold 876,000 shares of the business’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $11.82, for a total value of $10,354,320.00. Following the completion of the transaction, the director now owns 22,179,358 shares in the company, valued at approximately $262,160,011.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Roivant Sciences Trading Down 0.8 %

Shares of NASDAQ:ROIV opened at $11.48 on Friday. The company has a quick ratio of 27.91, a current ratio of 27.91 and a debt-to-equity ratio of 0.05. The company’s 50-day moving average price is $11.50 and its 200 day moving average price is $11.08. The company has a market cap of $8.48 billion, a PE ratio of 2.27 and a beta of 1.25. Roivant Sciences Ltd. has a fifty-two week low of $8.24 and a fifty-two week high of $13.24.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The company had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. During the same quarter in the previous year, the company posted ($0.38) earnings per share. The business’s revenue for the quarter was up 155.1% compared to the same quarter last year. Sell-side analysts anticipate that Roivant Sciences Ltd. will post -1.14 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in shares of Roivant Sciences during the second quarter valued at $34,000. Point72 Hong Kong Ltd bought a new stake in shares of Roivant Sciences during the 2nd quarter worth about $36,000. Quarry LP acquired a new stake in shares of Roivant Sciences in the 2nd quarter worth approximately $53,000. Acadian Asset Management LLC bought a new position in shares of Roivant Sciences in the first quarter valued at approximately $72,000. Finally, Fifth Third Wealth Advisors LLC acquired a new position in shares of Roivant Sciences during the second quarter valued at approximately $101,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ROIV shares. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Thursday, September 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Bank of America increased their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. Finally, Piper Sandler lifted their price target on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $17.39.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.